An interventional study of The level of PEEP during noninvasive ventilation in Noninvasive Ventilation, Pneumonia and ARDS, sponsored by Chongqing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Chongqing Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies in Pneumonia with a site in China — 44 open to participants now, 48 under way, 2 of them phase 3. Pneumonia · China.
Among the 142 studies in Pneumonia with a site in China, this one is the 15th largest by planned enrollment of the 94 interventional ones that give a count, is one of 13 that started in 2026, is one of 36 with no phase, reaches primary completion later than 47 of the 47 other live ones, and was the 128th registered.
1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.
Browse Pneumonia studies →44 of the 142 studies in Pneumonia with a site in China are open now. Recruiting first, the newest first:
Shandong University · Sites in China
Ages 65–110
Beijing Continent Pharmaceutical Co, Ltd. · Sites in China
Ages 18–75
Zhongnan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–80
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 17 · Phase 3 21 · Phase 4 14
First in 2003; this study’s year is marked. 13 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 706 is above the median of 128 across 978 interventional studies indexed under Pneumonia.
Median enrollment 154 across the 94 interventional studies, 350 across the 48 observational. Of the 51 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 142 have an industry lead sponsor. The 10 most frequent:
Chongqing Medical University is the lead sponsor of 78 studies on the registry; 17 are open to participants now.
Chongqing Medical University has 2 studies filed under Pneumonia — fewer than ten, so there is no comparison to draw.
11 of the studies in Pneumonia with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07388680Phase 3Beijing Continent Pharmaceutical Co, Ltd.Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia | 2026-12-30 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT07461714Guangzhou Medical UniversityAI-Driven Accurate Diagnosis of Pathogens in Severe Pneumonia | 2026-12-31 |
| NCT02738645Beijing Chao Yang HospitalA Clinical Cohort Study of Pneumonia in Respiratory Intensive Care Unit | 2026-12-31 |
| NCT07311343Beijing Tiantan HospitalOral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 142 studies in Pneumonia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Noninvasive ventilation is commonly employed in patients with pneumonia or acute respiratory distress syndrome (ARDS) and has been shown to reduce the need for intubation and invasive mechanical ventilation. However, the rate of noninvasive ventilation failure remains substantial, at approximately 40%. Compared with patients in whom noninvasive ventilation succeeds, those who experience noninvasive ventilation failure have a higher likelihood of mortality during their intensive care unit or hospital stay. Therefore, improving the success rate of noninvasive ventilation is clinically important. In patients with lung consolidation receiving invasive mechanical ventilation, high positive end-expiratory pressure (PEEP) can improve oxygenation. Noninvasive ventilation operates on similar physiological principles and can also deliver high PEEP via a mask interface. Nevertheless, there is limited evidence regarding the use of high PEEP during mask-delivered noninvasive ventilation. This study aimed to evaluate whether high PEEP can increase intubation-free survival in patients with pneumonia or ARDS who are treated with noninvasive ventilation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in high PEEP group will received 10 to 15 cmH2O of PEEP during noninvasive ventilation.
Procedure: The level of PEEP during noninvasive ventilation
Patients in low PEEP group will received 5 cmH2O of PEEP during noninvasive ventilation.
Procedure: The level of PEEP during noninvasive ventilation
In patients receiving noninvasive ventilation, participants will be randomly assigned to either a low or a high PEEP group. In the high PEEP group, PEEP will be set between 10 and 15 cmH2O. In the low PEEP group, PEEP will be maintained at 5 cmH2O.
28-day intubation-free survival
Time frame: from randomization to 28 days after randomization
28-day intubation rate
Time frame: from randomization to 28 days after randomization
the need for intubation within 28 days
The rate of the need for intubation within 28 days after randomization was assessed by two independent reviewers with extensive critical care experience.
Time frame: from randomization to 28 days after randomization
28-day survival
Time frame: from randomization to 28 days after randomization
7-category ordinal scale for clinical improvement at 28 days
The 7-category ordinal scale is as follows: 1 = not hospitalized and has resumed normal activities; 2 = not hospitalized but unable to resume normal activities; 3 = hospitalized without requiring supplemental oxygen; 4 = hospitalized and requiring supplemental oxygen; 5 = hospitalized and requiring HFNC, NIV, or both; 6 = hospitalized and requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; 7 = death.
Time frame: from randomization to 28 days after randomization
28-day invasive ventilator-free days
Time frame: from randomization to 28 days after randomization
28-day noninvasive ventilator days
Time frame: from randomization to 28 days after randomization
Length of ICU stay
Time frame: up to 24 weeks
Length of hospital stay
Time frame: up to 24 weeks
ICU mortality
Time frame: up to 24 weeks
Hospital mortality
Time frame: up to 24 weeks
60-day mortality
Time frame: from randomization to 60 days after randomization
Plan to share: No — These study data contain ethnic demographic information. Since it remains unclear whether Chinese laws permit the public disclosure of such data upon the completion of the research, a decision has been made to temporarily withhold data sharing during the study design phase.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2029, 47 months after the start.
Of 260 non-industry interventional studies with no phase under Pneumonia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 47 months is above that.
Counting every sponsor, half of 267 studies reached it within 22 months; a quarter within 11 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chongqing Medical University